AbbVie (NYSE: ABBV) has announced the acquisition of US-based biotechnology company Mitokinin, exercising an exclusive right obtained in 2021. The acquisition was contingent upon the successful completion of pre-clinical studies on Mitokinin’s lead program, a potential first-in-class PINK1 activator for the treatment of Parkinson’s disease (PD).
Details of the Acquisition
AbbVie will pay USD 110 million for Mitokinin, with shareholders eligible to receive additional milestone payments of up to USD 545 million, plus sales royalties from the PINK1 program. This strategic move underscores AbbVie’s commitment to expanding its pipeline in neurodegenerative diseases and highlights the potential of Mitokinin’s technology in the field.
Potential Impact of PINK1 Activator in Parkinson’s Disease
Familial forms of Parkinson’s disease are caused by mutations in the PINK1 protein, which is crucial for the turnover of dysfunctional mitochondria. Mitokinin’s candidate has shown promise in selectively enhancing the active form of PINK1 in damaged mitochondria without disrupting its regulation, positioning it as a potential disease-modifying treatment for PD.
Conclusion
The acquisition of Mitokinin by AbbVie marks a significant step in the development of novel therapies for Parkinson’s disease. With the potential to offer a disease-modifying approach, the PINK1 activator could transform the treatment landscape for patients suffering from this debilitating condition.-Fineline Info & Tech
